Videos

There is a need for new medications for depression to overcome high rates of treatment resistance.

The prevalence of NAFLD in the pediatric population has increased in recent years.

Dr. Kenneth J. Warrington led the panel in discussing various topics in rheumatology.

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.

Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.

Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.

Desai discusses the potential long-term effects of mavacamten and what it could mean for a patient population with HCM.

Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.

A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.

Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.

The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.

The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.

New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.

Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.

The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.

An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.

New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.